<SEC-DOCUMENT>0001193125-24-201376.txt : 20240815
<SEC-HEADER>0001193125-24-201376.hdr.sgml : 20240815
<ACCEPTANCE-DATETIME>20240815165337
ACCESSION NUMBER:		0001193125-24-201376
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240815
DATE AS OF CHANGE:		20240815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280061
		FILM NUMBER:		241213183

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d864499d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-280061</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT NO. 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated June
24, 2024) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g864499snap1.jpg" ALT="LOGO" STYLE="width:1.47986in;height:0.509028in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plus Therapeutics Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 10,774,596 Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the prospectus, dated June&nbsp;24, 2024 (as supplemented to date, the &#147;Prospectus&#148;), which forms
a part of our registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (<A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000119312524167044/d840996d424b3.htm">No. <FONT STYLE="white-space:nowrap">333-280061</FONT></A>). This
prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange
Commission on August&nbsp;15, 2024 (the &#147;Current Report&#148;). Accordingly, we have attached the Form <FONT STYLE="white-space:nowrap">8-K</FONT> to this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement relate to the issuance by us of up to 10,774,596 shares of our common stock, par value $0.001 (&#147;Common
Stock&#148;), consisting of: (i)&nbsp;up to 1,439,988 shares of Common Stock; (ii)&nbsp;up to 2,151,544<B> </B>shares of Common Stock issuable upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants; (iii)&nbsp;up to 3,591,532
shares of common stock issuable upon exercise of Series A Common Stock warrants; and (iv)&nbsp;up to 3,591,532 shares of Common Stock issuable upon exercise of Series B common stock warrants, originally issued to the selling stockholders in the May
2024 PIPE Financing, as described in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on The Nasdaq Capital Market LLC under the symbols &#147;PSTV&#148;. On
August&nbsp;14, 2024, the closing price of our Common Stock was $1.42. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; for purposes of federal securities
laws and are subject to reduced public company reporting requirements. Accordingly, the information in the Prospectus and this prospectus supplement may not be comparable to information provided by companies that are not smaller reporting companies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our business and investment in our Common Stock involve significant risks. These risks are described in the section titled &#147;Risk Factors&#148;
beginning on page 13 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is August&nbsp;15, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Current
Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section 13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August 15, 2024 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-34375</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0827593</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>4200 Marathon Blvd., Suite 200, Austin, Texas 78756</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices, with zip code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(737) <FONT STYLE="white-space:nowrap">255-7194</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Common Stock, par value $0.001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">PSTV</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Capital Market</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;&#8201;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&#8201;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9744; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;5.07</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Submission of Matters to a Vote of Security Holders. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2024 Annual Meeting of Stockholders of Plus Therapeutics, Inc. (the &#147;Company&#148;) was held on August&nbsp;15, 2024 (the &#147;Annual Meeting&#148;).
At the Annual Meeting, the Company&#146;s stockholders voted on four proposals, as described in the Company&#146;s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on July&nbsp;10, 2024 (the &#147;Proxy
Statement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had 5,704,219 shares of common stock issued and outstanding at the close of business on June&nbsp;25, 2024, the record date
for eligibility to vote at the Annual Meeting. The holders of 2,484,122 shares of the Company&#146;s issued and outstanding common stock were represented in person virtually or represented by valid proxy at the Annual, constituting a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vote results detailed below represent final results as certified by the inspector of elections. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.&nbsp;1 &#150; Election of Directors. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company to hold office for a term expiring at the Company&#146;s Annual Meeting of Stockholders in 2025 and until
each such person&#146;s successors is duly elected and qualified, or until his or her earlier death, resignation or removal: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Votes For</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Votes&nbsp;Withheld</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">Broker&nbsp;Non-Votes</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,175,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,178,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,159,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,183,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,176,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,183,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.&nbsp;2 &#150; Ratification of Appointment of Independent Registered Public Accounting Firm. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s stockholders ratified the appointment of BDO USA, P.C. as the Company&#146;s registered public accounting firm for the 2024 fiscal year. The
votes regarding this proposal were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Votes For</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Votes&nbsp;Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Abstentions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><FONT STYLE="white-space:nowrap">Broker&nbsp;Non-Votes</FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">2,434,053</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">44,854</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,215</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.&nbsp;3 &#150; Advisory Vote on the Compensation of Our Named Executive Officers. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s stockholders approved, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation of the Company&#146;s
named executive officers.&nbsp;The votes regarding this proposal were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Votes For</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Votes&nbsp;Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Abstentions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><FONT STYLE="white-space:nowrap">Broker&nbsp;Non-Votes</FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">1,115,004</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">163,917</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4,362</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,200,839</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.&nbsp;4 &#150; Amendment and Restatement of the Company&#146;s 2020 Stock Incentive Plan. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s stockholders approved the fourth amendment and restatement of the Company&#146;s 2020 Stock Incentive Plan. The votes regarding this
proposal were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Votes For</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Votes&nbsp;Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Abstentions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><FONT STYLE="white-space:nowrap">Broker&nbsp;Non-Votes</FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">1,097,650</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">182,432</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,201</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,200,839</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;15, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc H. Hedrick, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief
Executive Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g864499snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g864499snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MC3>G_;Q]TU]\?F!^9/[>_'BOX7^VB>)OPQ?Z-7Y+XE)^UP%NE*7_ *6?N7A
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86!>8"1F B32?E_7Y%QT2\CU&C;Y#/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
